DailyDoctor Archive Specialties Get app
Back to the 1 November 2026 edition

Research · 02 of 06

Proton pump inhibitors blurred the CYP2C19 genotype signal for escitalopram

When a patient on escitalopram takes omeprazole or esomeprazole, do not rely on CYP2C19 genotype alone.

Design
Retrospective analysis of therapeutic drug monitoring and genotype data with mass-spectra reprocessing
Population
2818 CYP2C19-genotyped patients on escitalopram in Norway, 445 with PPI use
Primary outcome
N-desmethylescitalopram to escitalopram ratio in ultrarapid vs poor metabolisers
Effect
4.5-fold difference without PPI; 2.8-fold with pantoprazole; 1.8-fold with omeprazole/esomeprazole

A study in Clinical Pharmacology & Therapeutics, published on 14 October, reanalysed therapeutic drug monitoring samples from 2818 CYP2C19-genotyped patients on escitalopram in Oslo. Mass spectra were reprocessed to detect proton pump inhibitor (PPI) use, found in about 16%.

Without a PPI, ultrarapid metabolisers had a 4.5-fold higher metabolic ratio than poor metabolisers, as genotype predicts. With pantoprazole the gap shrank to 2.8-fold, and with omeprazole or esomeprazole to 1.8-fold. In other words, PPIs pushed fast metabolisers towards behaving like slow ones, a phenomenon called phenoconversion.

For prescribers, this means a CYP2C19 genotype result can mislead if the patient is also on a PPI, especially omeprazole or esomeprazole. Escitalopram exposure may be higher than the genotype suggests.

The study measured metabolism, not side effects or response, so the clinical consequence is inferred.

  • Check for PPI use when interpreting a CYP2C19 genotype in a patient on escitalopram.
  • Expect omeprazole and esomeprazole to inhibit CYP2C19 more than pantoprazole.
  • Consider pantoprazole if a PPI is needed alongside a CYP2C19-dependent drug.
  • Watch for dose-related effects, such as QT prolongation, when escitalopram exposure may be raised.

Why it matters

Genotype-guided prescribing can mislead when a common co-medication changes the phenotype.

The statistics, in plain English

A metabolic ratio compares metabolite with parent drug: higher means faster metabolism. The fall from a 4.5-fold to a 1.8-fold genotype difference with omeprazole or esomeprazole was not statistically significant in that subgroup (P = 0.2), likely because few patients were in it.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

interactionspkpdtdmpharmacogenomicsdrugsafetysignalregulatoryscidosing

Tomorrow morning, before your first patient

One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app